leadf
logo-loader
AIM:SNG OTC:SYGGF FRA:OMY

Synairgen PLC

Receive alerts
Market:
AIM
Market Cap:
£322.75 m
Price
160.30 GBX
Change
-1.23%
52 weeks high
233.60
52 weeks low
74.80

In brief

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

Snapshot

  • Synairgen says COVID treatment has shown potent antiviral activity against two variants
  • Demand for healthcare stocks similar to late 90s tech boom, says analyst
  • Synairgen price target maintained at 505p by broker finnCap
  • Synairgen mark 'incredible year' working towards COVID-19 treatment